These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2469127)

  • 21. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
    Wirth MP; Pilarsky C
    Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J; Lorente JA; Encabo G
    Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
    Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
    Okubo Y; Ito T
    Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A survey of radical surgery without neoadjuvant therapy for patients with stage B and C prostatic carcinoma].
    Matsuzaki J; Kanda F; Watanabe T; Ouchi H; Tsuchiya F; Fukuda M; Satomi Y
    Hinyokika Kiyo; 2001 Jan; 47(1):5-10. PubMed ID: 11235223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course].
    Sáenz de Chirife AM; Bassi AM; Celeste F; Bergdolt D
    Arch Esp Urol; 1991 May; 44(4):405-9. PubMed ID: 1712189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
    Tarle M
    Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate specific antigen in serum of the patients with prostatic cancer].
    Akimoto S; Akakura K; Fuse H; Shimazaki J
    Hinyokika Kiyo; 1988 Apr; 34(4):636-42. PubMed ID: 2456678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of PSA in prostatic adenocarcinoma].
    Manca GP
    Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Value of prostate-specific antigen as prognostic factor of metastatic cancer of the prostate].
    Morote Robles J; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
    Actas Urol Esp; 1992 May; 16(5):394-7. PubMed ID: 1380754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PSA variations in persons with latent prostate cancer].
    Stamatiou K; Danciu M; Karakos C; Sofras F
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):126-9. PubMed ID: 18677916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The present role of prostatic specific antigen (PSA) as a tumor marker in carcinoma of the prostate.
    Parra RO
    Mo Med; 1991 Jun; 88(6):349-52. PubMed ID: 1712422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical evaluation of prostate antigen (PA) in prostate cancer].
    Kuriyama M
    Gan No Rinsho; 1985 May; 31(6 Suppl):606-10. PubMed ID: 2411962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prostatic carcinoma in a young adult: a case report].
    Yamamoto S; Senzaki A; Yamagiwa K; Tanaka T; Oda T
    Hinyokika Kiyo; 1990 May; 36(5):617-22. PubMed ID: 1698013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.